OSTX · Insider Trading
OS Therapies Incorporated
Every open-market purchase and sale reported by OSTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | Kerry M Clem | Chief Commercial Officer | A | +200,000 | — |
| 2026-11-12 | Knuettel Francis II | Chief Financial Officer | A | +250,000 | — |
| 2026-10-30 | Knuettel Francis II | Chief Financial Officer | A | — | — |
| 2026-10-30 | Olivier Roger Jarry | Director | A | +300,000 deriv. | — |
| 2026-10-30 | Paul A. Romness | President and CEO | A | — | — |
| 2026-10-30 | Craig Eagle | Director | A | +300,000 deriv. | — |
| 2026-10-30 | Theodore F. Search | Director | A | — | — |
| 2026-10-30 | Robert Petit | See Remarks | A | — | — |
| 2026-10-30 | Avril Suzette McKean-Dieser | Director | A | — | — |
| 2026-10-30 | John Ciccio | Director | A | — | — |
| 2026-10-30 | Kerry M Clem | Chief Commercial Officer | A | — | — |
| 2026-02-13 | Olivier Roger Jarry | Director | A | +50,000 deriv. | — |
| 2026-02-13 | Robert Petit | See Remarks | A | — | — |
| 2026-02-13 | Karim Galzahr | Director | A | +50,000 deriv. | — |
| 2026-02-13 | Paul A. Romness | President and CEO | A | — | — |
| 2026-02-13 | John Ciccio | Director | A | — | — |
| 2026-02-13 | Paul A. Romness | President and CEO | A | — | — |
| 2026-02-13 | Avril Suzette McKean-Dieser | Director | A | — | — |
| 2026-02-13 | Theodore F. Search | Director | A | — | — |
| 2026-02-13 | Christopher P. Acevedo | Chief Financial Officer | A | — | — |
| 2025-12-19 | Olivier Roger Jarry | Director | A | +140,000 deriv. | — |
| 2025-12-19 | Karim Galzahr | Director | A | +140,000 deriv. | — |
| 2025-12-19 | Christopher P. Acevedo | Chief Financial Officer | A | — | — |
| 2025-12-19 | Paul A. Romness | President and CEO | A | — | — |
| 2025-12-19 | Robert Petit | See Remarks | A | — | — |
| 2025-12-19 | John Ciccio | Director | A | — | — |
| 2025-12-19 | Theodore F. Search | Director | A | — | — |
| 2025-12-19 | Avril Suzette McKean-Dieser | Director | A | — | — |
| 2025-05-09 | Einodmil LLC | 10%+ Owner | Sell | −82,000 | −$163.92K |
| 2025-04-11 | Shalom Auerbach | 10%+ Owner | Sell | −60,012 | −$81.57K |
| 2025-02-28 | Paul A. Romness | President and CEO | J | +225,000 | — |
| 2025-02-28 | Shalom Auerbach | 10%+ Owner | J | −225,000 | −$369.00K |
| 2025-02-18 | Shalom Auerbach | 10%+ Owner | Sell | −100,000 | −$284.30K |
| 2025-01-17 | Einodmil LLC | 10%+ Owner | Sell | −16,720 | −$112.61K |
| 2025-01-14 | Einodmil LLC | 10%+ Owner | C | +1,766,927 | — |
| 2024-08-06 | John Ciccio | Director | C | +398,335 | — |
| 2024-08-06 | Theodore F. Search | Director | C | +398,335 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Shalom Auerbach | 10%+ Owner | 2,769,570 | $2.27M |
| Einodmil LLC | 10%+ Owner | 2,687,570 | $2.20M |
| Paul A. Romness | President and CEO | 2,473,000 | $2.03M |
| John Ciccio | Director | 455,835 | $373.92K |
| Theodore F. Search | Director | 455,835 | $373.92K |
| Knuettel Francis II | Chief Financial Officer | 270,000 | $221.48K |
| Kerry M Clem | Chief Commercial Officer | 225,000 | $184.57K |
| Robert Petit | See Remarks | 200,000 | $164.06K |
| Christopher P. Acevedo | Chief Financial Officer | 109,375 | $89.72K |
| Avril Suzette McKean-Dieser | Director | 5,000 | $4.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OSTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.